+検索条件
-Structure paper
タイトル | Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen. |
---|---|
ジャーナル・号・ページ | Nat Commun, Vol. 14, Issue 1, Page 5063, Year 2023 |
掲載日 | 2023年8月21日 |
著者 | Katharine M Wright / Sarah R DiNapoli / Michelle S Miller / P Aitana Azurmendi / Xiaowei Zhao / Zhiheng Yu / Mayukh Chakrabarti / WuXian Shi / Jacqueline Douglass / Michael S Hwang / Emily Han-Chung Hsiue / Brian J Mog / Alexander H Pearlman / Suman Paul / Maximilian F Konig / Drew M Pardoll / Chetan Bettegowda / Nickolas Papadopoulos / Kenneth W Kinzler / Bert Vogelstein / Shibin Zhou / Sandra B Gabelli / |
PubMed 要旨 | Specificity remains a major challenge to current therapeutic strategies for cancer. Mutation associated neoantigens (MANAs) are products of genetic alterations, making them highly specific ...Specificity remains a major challenge to current therapeutic strategies for cancer. Mutation associated neoantigens (MANAs) are products of genetic alterations, making them highly specific therapeutic targets. MANAs are HLA-presented (pHLA) peptides derived from intracellular mutant proteins that are otherwise inaccessible to antibody-based therapeutics. Here, we describe the cryo-EM structure of an antibody-MANA pHLA complex. Specifically, we determine a TCR mimic (TCRm) antibody bound to its MANA target, the KRAS peptide presented by HLA-A*03:01. Hydrophobic residues appear to account for the specificity of the mutant G12V residue. We also determine the structure of the wild-type G12 peptide bound to HLA-A*03:01, using X-ray crystallography. Based on these structures, we perform screens to validate the key residues required for peptide specificity. These experiments led us to a model for discrimination between the mutant and the wild-type peptides presented on HLA-A*03:01 based exclusively on hydrophobic interactions. |
リンク | Nat Commun / PubMed:37604828 / PubMed Central |
手法 | EM (単粒子) / X線回折 |
解像度 | 2.594 - 3.14 Å |
構造データ | EMDB-25427, PDB-7stf: PDB-8dvg: |
化合物 | ChemComp-SO4: ChemComp-PEG: ChemComp-HOH: |
由来 |
|
キーワード | IMMUNE SYSTEM / Complex / MHC-I / KRAS / HLA-A3 / immunotherapy |